- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02734277
Type 1-diabetesutvidelsesstudie (T1DES)
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D).
This observational study will:
- follow participants to determine how long they continue to produce insulin, and
- will also assess how changes in the immune system over time relate to the ability to produce insulin.
This information could help design better therapies for type 1 diabetes in the future.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Depending upon a participant's level of insulin production, participation may be as short as one return visit or a maximum of five years. Evaluation visits will include:
- Overall health assessments
- Blood and urine collections
- Mixed meal tolerance test (MMTTs) for certain participants, per protocol.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiesteder
-
-
California
-
San Francisco, California, Forente stater, 94143
- Rekruttering
- UCSF School of Medicine
-
Ta kontakt med:
- Rebecca Wesch
- Telefonnummer: 415-476-5984
- E-post: rebecca.wesch@ucsf.edu
-
Hovedetterforsker:
- Stephen Gitelman, MD
-
Stanford, California, Forente stater, 94305
- Rekruttering
- Stanford University
-
Ta kontakt med:
- Trudy Esrey
- Telefonnummer: 650-498-4450
- E-post: tesrey@stanford.edu
-
Hovedetterforsker:
- Darrell Wilson, MD
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Rekruttering
- University of Colorado School of Medicine: Barbara Davis Center for Diabetes
-
Hovedetterforsker:
- Peter Gottlieb, MD
-
Ta kontakt med:
- Mara Kinney
- Telefonnummer: (303) 724-8272
- E-post: MARA.KINNEY@ucdenver.edu
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06519
- Fullført
- Yale University
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Tilbaketrukket
- Emory University
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Rekruttering
- Indiana University Riley Hospital for Children
-
Ta kontakt med:
- Ellie Ryan
- Telefonnummer: 317-278-7037
- E-post: elmryan@iu.edu
-
Ta kontakt med:
- Maria Spall
- Telefonnummer: 317-278-7034
- E-post: malnicho@iu.edu
-
Hovedetterforsker:
- Linda DiMeglio, MD, MPH
-
-
Iowa
-
Iowa City, Iowa, Forente stater, 52242
- Rekruttering
- University of Iowa Health Care Division of Pediatric Endocrinology
-
Ta kontakt med:
- Joanne Cabbage
- Telefonnummer: 319-356-4035
- E-post: joanne-cabbage@uiowa.edu
-
Hovedetterforsker:
- Michael Tansey, MD
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02215
- Rekruttering
- Joslin Diabetes Center
-
Ta kontakt med:
- Site Public Contact
- Telefonnummer: 888-813-8669
- E-post: T1DTrials@joslin.harvard.edu
-
Hovedetterforsker:
- Jason Gaglia, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55454
- Rekruttering
- University of Minnesota
-
Ta kontakt med:
- Anne Street
- Telefonnummer: 612-625-9709
- E-post: stree065@umn.edu
-
Hovedetterforsker:
- Antoinette Moran, MD
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64108
- Fullført
- Children's Mercy Hospital
-
-
South Dakota
-
Sioux Falls, South Dakota, Forente stater, 57104
- Fullført
- Sanford Research
-
-
Washington
-
Seattle, Washington, Forente stater, 98101
- Rekruttering
- Benaroya Research Institute
-
Hovedetterforsker:
- Sandra Lord, MD
-
Ta kontakt med:
- Katie Bennett
- Telefonnummer: (206) 341-8945
- E-post: kbennett@benaroyaresearch.org
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Former participants in Immune Tolerance Network (ITN) new-onset Type 1 Diabetes Mellitus (T1DM) studies with immunomodulatory agents as the intervention.
Beskrivelse
Inclusion Criteria:
- Prior participant in an Immune Tolerance Network (ITN) executive committee approved T1DM study.
- Ability to sign informed consent/assent (as applicable for children).
Exclusion Criteria:
- Any medical condition that in the opinion of the principal investigator would interfere with safe completion of the trial; or
- Inability to comply with the study visit schedule and required assessments.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Group 1: Detectable C-peptide by MMTT
Participants with detectable C-peptide at their:
Detectable C-peptide is defined as a value above the lower limit of detection. |
|
Group 2:Undetectable C-peptide by MMTT
Participants without detectable C-peptide at their:
Undetectable C-peptide is defined as a value below the lower limit of detection. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Beta Cell Function by MMTT-Stimulated Mean C-peptide Area Under the Curve (AUC)
Tidsramme: Baseline (Visit 0) to Month 60 (Year 5)
|
Evaluation of changes in beta cell function over time will be measured by mixed-meal tolerance test (MMTT) -Stimulated mean C-Peptide area under the curve (AUC). C-peptide is released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin. Detectable C-peptide is defined as any value during a MMTT of ≥0.15 ng/mL. |
Baseline (Visit 0) to Month 60 (Year 5)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Insulin Use in Units per Kilogram Body Weight Per Day
Tidsramme: Baseline (Visit 0) to Month 60 (Year 5)
|
The need to use exogenous insulin is an indication that the body is not producing enough endogenous insulin. Higher amounts of insulin use indicate higher disease activity. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Change in HbA1C
Tidsramme: Baseline (Visit 0) to Month 60 (Year 5)
|
Glycosylated hemoglobin (HbA1c) is a measure of the average plasma concentration of blood sugar (glucose) over the previous three months and measures the level of optimal management of underlying disease. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Count of Participant-Reported Major Hypoglycemic Events
Tidsramme: Baseline (Visit 0) to Month 60 (Year 5)
|
Major hypoglycemic events are defined as a glucose concentration <55 mg/dL (grades 2-5, NCI-CTCAE version 4.03), or clinically: involving seizure(s) or involving loss of consciousness (coma), or requiring assistance from another individual in order to recover. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Time to Undetectable C-Peptide
Tidsramme: Baseline (Visit 0) to Month 60 (Year 5)
|
To assess the longevity of beta cell function, time to undetectable C-peptide will be evaluated using Kaplan-Meier survival estimates. |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Frequency of Grade 3 or Higher Adverse Events (AEs) of Interest
Tidsramme: Baseline (Visit 0) to Month 60 (Year 5)
|
Events of interest include but are not limited to:
Reference for Grade 3 or higher AEs: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (June 14, 2010). |
Baseline (Visit 0) to Month 60 (Year 5)
|
|
Severity of Grade 3 or Higher Adverse Events (AEs) of Interest
Tidsramme: Baseline (Visit 0) to Month 60 (Year 5)
|
Events of interest include but are not limited to:
Reference for Grade 3 or higher AEs: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03 (June 14, 2010). |
Baseline (Visit 0) to Month 60 (Year 5)
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Studiestol: Linda A. DiMeglio, MD, MPH,MA, Riley Hospital for Children at Indiana University Health
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA; AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013 Nov;62(11):3766-74. doi: 10.2337/db13-0345. Epub 2013 Jul 8.
- Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015 Aug 3;125(8):3285-96. doi: 10.1172/JCI81722. Epub 2015 Jul 20.
- Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94. doi: 10.1016/S2213-8587(13)70111-6. Epub 2013 Sep 23.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Antatt)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- DAIT ITN066AI
- NIAID CRMS ID#: 20722 (Annen identifikator: DAIT NIAID)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
The plan is to share data in: 1.)ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools that are available to researchers who register online and subsequently receive DAIT approval; and 2.)TrialShare, a clinical trials research portal developed by the Immune Tolerance Network that makes data from the consortium's clinical trials publicly available without charge.
IPD-delingstidsramme
After completion of the study.
Tilgangskriterier for IPD-deling
Will be available to the public.
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .